Chronic heart failure (CHF) is characterized by the activation of neurohormones and cytokines. This study determined whether peak oxygen uptake (VO 2 ) can be predicted by the degree of neurohormonal and cytokine activations in CHF. Plasma norepinephrine, epinephrine, renin-angiotensin system activity, ANP, BNP, and serum interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α were measured in 84 CHF patients (age, 59 ± 1 years, LVEF, 36 ± 1%) and 34 controls. Maximal cardiopulmonary exercise testing was performed. Peak VO 2 (Controls vs CHF: 27.8 ± 1.3 vs 18.2 ± 0.5 mL/min/kg, P < 0.0001) was lower in CHF. Patients with CHF had increased plasma norepinephrine (211 ± 11 vs 315 ± 24 pg/mL), renin activity (1.2 ± 0.2 vs 6.2 ± 1.1 ng/mL/hr), ANP (22 ± 3 vs 72 ± 7 pg/mL), and BNP levels (18 ± 3 vs 200 ± 25 pg/mL) (all P < 0.01). Serum IL-6 (1.1 ± 0.1 vs 2.4 ± 0.3 pg/mL) and TNF-α (2.7 ± 0.2 vs 4.0 ± 0.3 pg/mL) levels were higher in CHF (both P < 0.001). Univariate analysis revealed that age (P < 0.001), cardiothoracic ratio (P < 0.001), norepinephrine (P < 0.0001), ANP (P < 0.001), BNP (P < 0.01), and log IL-6 (P < 0.05) were significantly related with peak VO 2 . Stepwise regression analysis indicated that plasma norepinephrine and ANP emerged as significant determinants of peak VO 2 , independent of patient age (overall R = 0.61, P < 0.0001). In summary, patients with CHF exhibited activation of neurohormones and proinflammatory cytokines. Among the elevated hormonal and cytokine markers, plasma norepinephrine and ANP levels were independent predictors of exercise capacity. (Jpn Heart J 2003; 44: 725-734) Key words: Heart failure, Peak oxygen uptake, Neurohormones, Cytokines, Cardiopulmonary exercise test CHRONIC heart failure (CHF) is characterized by the activation of neurohormones and cytokines.
the disease severity and prognosis. [4] [5] [6] In addition to these neurohormones, circulating proinflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α, are reported to be increased in patients with CHF. 7, 8) Although the precise role is unclear at present, both IL-6 and TNF-α appear to play a pathophysiological role in the development of CHF. 7, 8) Exercise intolerance is another important aspect in patients with CHF. For the assessment of functional capacity, cardiopulmonary exercise testing has been widely utilized in the clinical setting. Previous studies have showed that peak oxygen uptake (VO 2 ) obtained at maximal exercise provides not only an objective measure of functional capacity, but also prognostic information in patients with CHF. [9] [10] [11] [12] [13] [14] We predict that patients with exercise intolerance are those with higher neurohormonal and cytokine activation, however, the relation between peak VO 2 and multiple neurohormone/cytokine levels has not been clearly elucidated. Thus, we conducted the present study to clarify the relation between neurohormonal/cytokine activation and functional capacity as measured by cardiopulmonary exercise testing in patients with mild to moderate CHF.
METHODS

Subjects :
We studied 84 Japanese patients with CHF (68 men and 16 women, 59.4 ± 1.3 years) who had a left ventricular ejection fraction (LVEF) < 45%. We also studied 34 age-matched normal subjects (28 men and 6 women) who had no cardiovascular disease. Patients with inducible ischemia, significant pulmonary disease, intermittent claudication, or other disorders limiting exercise performance other than cardiac disease were excluded. Patients with chronic inflammatory disease, collagen disease, acute infection, or neoplasma were also excluded. The protocol was approved by the Ethics Committee of Tottori University and all subjects gave their written informed consent to participate in the study.
Chest X ray and echocardiographic assessment:
Cardiothoracic ratio was assessed from chest X rays. Echocardiographic studies were performed using a phased array sector scanner. Left ventricular volume was calculated using the Teichholz modification, 15) and left ventricular ejection fraction was calculated as [(end-diastolic volume -end-systolic volume) / end-diastolic volume] × 100. Determination of neurohormones and cytokines: Blood specimens were drawn through a plastic cannula placed in a forearm vein after 30 minutes of supine rest. Blood samples were determined as previously described. 16, 17) Briefly, plasma norepinephrine and epinephrine levels were determined by high performance liquid chromatography. Plasma renin activity, angiotensin II, and aldosterone were respectively. Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) levels were determined using a Shionoria RIA Kit and an S-1215 RIA kit (Shionogi, Osaka), respectively. Serum IL-6 levels were measured using chemiluminescent enzyme immunoassay (CLEIA, Fujirebio, Tokyo, Japan), and serum TNF-α levels were determined by a high-sensitivity human TNF-α test (Quantikine HS, R&D Systems, Minneapolis, MN, USA). The intra-assay variabilities in our laboratory for norepinephrine, epinephrine, plasma renin activity, angiotensin II, aldosterone, ANP, BNP, IL-6, and TNF-α are 1.8%, 6.0%, 5.4%, 6.3%, 6.0 %, 6.1%, 3.3%, 2.2%, and 5.3%, respectively. Cardiopulmonary exercise testing: Cardiopulmonary exercise testing was performed using an upright bicycle ergometer with a ramp protocol. After 3 minutes of unloaded cycling, the exercise load was increased in 10-watt/min increments. Patients stopped exercise when they had severe leg fatigue and/or dyspnea. Oxygen uptake (VO 2 ), carbon dioxide output (VCO 2 ), and minute ventilation (VE) were measured using a 280E Aeromonitor (Minato Medical Science, Osaka, Japan). Anaerobic threshold was determined by the V-slope method.
18) Peak VO 2 was defined as the maximal VO 2 attained during exercise. The slope of the VE-VCO 2 relationship was calculated by linear regression analysis using the values of VE and VCO 2 . Statistical analysis: Comparisons of the continuous variables between normal controls and in patients with CHF were performed using the Mann-Whitney Utest. Univariate analysis and stepwise multivariate linear regression analysis were used to detect independent predictors of peak VO 2 among 13 variables. Linear regression analysis was used to compare the relationship between the two variables. All analyses were performed with a StatView statistical program (Version 5.0, SAS Institute Inc. Cary, NC, USA). The differences were considered significant when P values were less than 0.05. Data are expressed as the mean ± SEM.
RESULTS
Baseline characteristics, neurohormones, and cytokines:
The demographic parameters and levels of neurohormones and cytokines are summarized in Table I . The etiology of CHF was idiopathic dilated cardiomyopathy in 44 patients, old myocardial infarction in 14 patients, valvular heart disease in 20 patients, hypertensive heart disease in 3, and others in 3 patients. At the time of the study, the patients were treated with loop-diuretics (67%), spironolactone (15%), digitalis (64%), angiotensin-converting enzyme inhibitors/antiotensin II receptor blockers (87%), β-blockers (20%), antiarrhythmic agents (11%), calcium channel antagonists (15%), long-acting nitrates (24%), antiplatelet agents (15%), and warfarin (20%).
Patients with CHF had larger cardiac dimensions and a lower left ventricular ejection fraction (Controls vs CHF: 70.1 ± 1.2 vs 36.1 ± 0.9%, P < 0.0001). The cardiothoracic ratio was larger in patients with CHF. Plasma norepinephrine, plasma renin activity, plasma ANP, and plasma BNP levels were significantly higher in patients with CHF compared to controls. Patients with CHF had significantly elevated serum IL-6 and TNF-α levels compared to controls. Cardiopulmonary exercise variables: The results of the cardiopulmonary exercise testing are shown in Figure 1 . Compared to normal controls, peak VO 2 (27.8 ± 1.4 vs 18.2 ± 0.5 mL/min/kg, P < 0.0001) was significantly lower in patients with CHF. Anaerobic threshold (AT) (16.3 ± 0.7 vs 11.1 ± 0.3 mL/min/kg, P < 0.0001) was lower, and VE/VCO 2 slope (27.5 ± 0.5 vs 34.1 ± 0.8, P < 0.0001) was steeper in patients with CHF. Peak respiratory exchange ratio (RER) was Values are mean ± SEM. *P < 0.05 vs Controls. CHF; chronic heart failure, LV; left ventricular, ANP; atrial natriuretic peptide, BNP; brain natriuretic peptide, IL-6; interleukin-6, TNF-α; tumor necrosis factor-α.
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Predictors of peak VO 2 in patients with CHF:
The results of univariate and multivariate analyses are summarized in Table II . Univariate analysis revealed that age (P = 0.002), cardiothoracic ratio (P = 0.0002), plasma norepinephrine (P < 0.0001), plasma ANP (P = 0.0012), plasma BNP (P = 0.0021), and log IL-6 (P = 0.0119) were significantly related with peak VO 2 in patients with CHF. To detect independent predictors of peak VO 2 , 13 variables including neurohormonal factors and cytokine levels, as well as important clinical factors were imputted into a stepwise multivariate model. Multivariate analysis revealed that the plasma levels of norepinephrine and ANP predicted peak VO 2 independent of patient age (Overall R = 0.61, P < 0.0001).
The relationships between plasma norepinephrine level and peak VO 2 and between plasma ANP level and peak VO 2 are shown in Figure 2 . Negative corre- Figure 1 . Cardiopulmonary exercise testing data are shown for normal control subjects (open bar) and for patients with chronic heart failure (CHF) (closed bar). Peak VO 2 and anaerobic threshold (AT) were significantly lower, and VE/VCO 2 slope was significantly steeper in patients with CHF. Peak respiratory exchange ratio (RER) was not significantly different between control subjects and patients with CHF. Values are mean ± SEM. * P < 0.05 vs control subjects.
lations were noted between these two neurohormonal factors and peak VO 2 in patients with CHF. 
DISCUSSION
In the current study, patients with mild to moderate CHF exhibited activation of neurohormones and proinflammatory cytokines. Among the elevated neurohormonal and cytokine markers, the plasma norepinephrine and ANP levels were independent predictors of exercise capacity as measured by cardiopulmonary exercise testing in patients with CHF. These findings suggest a possible link between neurohormonal activation and exercise intolerance in patients with CHF.
We investigated the relation between elevated neurohormonal/cytokine markers and objective measures of exercise tolerance, ie, peak VO 2 in patients with CHF. We confirmed that patients with CHF had neurohormonal activation, elevated proinflammatory cytokine levels, and reduced peak VO 2 . Univariate and multivariate analyses revealed that plasma levels of norepinephrine were significantly related to VO 2 at maximal exercise (Table II) . Although the correlation was modest, a significant inverse relationship was observed between plasma norepinephrine and peak VO 2 ( Figure 2 ). Other investigators have reported a similar inverse correlation (R value ranging from -0.44 to -0.50) between plasma norepinephrine and peak VO 2 . [19] [20] [21] This inverse relationship was confirmed by direct measurements of muscle sympathetic nerve activity. Notarius, et al 22) reported that reduced exercise capacity in CHF is related to increased efferent sympathetic nerve traffic to calf muscle, suggesting that the greater functional impairment is associated with higher sympathetic activation in patients with CHF.
It is critically important to emphasize that the correlation only demonstrates an association between high sympathetic nervous activity and peak VO 2 . High plasma norepinphrine may be an epiphenomenon and does not causally relate to the exercise intolerance. Nevertheless, it can be speculated that neurogenic vasoconstriction under high sympathetic activity serves as an important constraint on exercise blood flow in CHF patients. Abnormalities of peripheral perfusion have been well recognized in CHF. 23) Sympathetic activation, activation of the reninangiotensin system, and increased endothelin 24) all result in excessive vasoconsrtiction. Thus, it is reasonable to believe that high sympathetic nervous activity can lead to the impaired exercise tolerance in CHF.
In a multivariate model, we also found the plasma ANP level was an independent predictor of peak VO 2 . It is reported that patients with high ANP levels are those with elevated pulmonary artery and capillary wedge pressures. 25) Thus, altered central hemodynamics with higher intracardiac pressures may be attributed to the exercise intolerance in our patients with CHF. Previous studies reported that both ANP 26) and BNP levels 27) predict peak VO 2 in patients with CHF. When both natriuretic peptide levels were evaluated together, ANP pro-vided a better correlation with peak VO 2 , and remained as a significant factor in the multivariate analysis in our study. We believe, however, that the very similar R value (0.347 for ANP and 0.331 for BNP) indicates that each peptide can provide an equivalent predicting value for peak VO 2 in our patients with CHF. In this study, there were no significant correlations between plasma norepinephrine and ANP (r = 0.11, NS) or between plasma norepinephrine and BNP (r = 0.16, NS), suggesting that plasma norepinephrine concentration and natriuretic peptide concentration provide independent information for predicting peak VO 2 in our patients with CHF. Study limitations: This study has several limitations. First, we acknowledge the that various medications taken may have influenced the neurohormones and cytokines. Among them, circulating renin-angiotensin system activity can be influenced by diuretics and neurohormonal antagonists. Thus, the interpretation of the levels of renin-angiotensin system activity warrants caution. Second, patients with severe CHF are those with the most significant neurohormonal and cytokine activation, and it is of interest to determine the relation between peak VO 2 and humoral factors in such patients. However, our ability to evaluate these patients is limited by their ability to exercise. Finally, because this is a cross-sectional study, the prognostic impacts of peak VO 2 and various neurohormonal and cytokine markers have not been evaluated. Previously, some investigators 28, 29) reported that neurohormonal measurements provide better prognostic information than peak VO 2 , while others 30) found that peak VO 2 is more potent than BNP as a prognostic parameter. Further study is necessary to evaluate the prognostic importance of neurohormones, cytokines, and cardiopulmonary exercise parameters in patients with CHF. Conclusions: We evaluated multiple neurohormonal factors and proinflammatory cytokines in relation to peak VO 2 in patients with CHF. The results of this study showed that patients with mild to moderate CHF had high plasma levels of norepinephrine, renin activity, natriuretic peptides, and high serum levels of IL-6 and TNF-α. Among the elevated hormonal and cytokine markers, plasma norepinephrine and ANP levels were independent predictors of peak VO 2 in patients with CHF.
